Azafaros
Dr Christian Freitag brings many years of pharmaceutical industry experience to his role as Chief Medical Officer with Azafaros. He started his career in the pharmaceutical industry at Hoffmann-La Roche in pharmacovigilance and medical affairs. At Shire, he held several positions in clinical development and medical affairs, covering the internal medicine portfolio, and latterly as VP, Global Clinical development and Innovation. In 2014 he joined BTG plc in the UK as SVP to head up Vascular Medicine, moving on to become responsible for global clinical development across the portfolio. He joined Debiopharm International SA in 2016 where he led the clinical R&D function, managing international drug development from clinical trial phases 1 to III. More recently, he joined Dynacure as Chief Medical Officer where he was responsible for medical and regulatory strategy, including clinical development of the lead compound in CNM.
He obtained his medical degree from Kiel University, Germany in 1994.
This person is not in any offices
Azafaros
Azafaros is developing new treatment options to help patients with rare metabolic disorders. Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential.